Market Closed -
Nasdaq
02:00:01 07/05/2024 am IST
|
5-day change
|
1st Jan Change
|
1.31
USD
|
-1.50%
|
|
-3.31%
|
+92.65%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
38.91
|
26.6
|
46.74
|
10.04
|
6.392
|
12.31
|
-
|
-
|
Enterprise Value (EV)
1 |
38.91
|
26.6
|
46.74
|
10.04
|
6.392
|
12.31
|
12.31
|
12.31
|
P/E ratio
|
-2.22
x
|
-1.06
x
|
-2.11
x
|
-0.27
x
|
-0.31
x
|
-0.58
x
|
-0.77
x
|
-0.76
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
77.8
x
|
53.2
x
|
93.5
x
|
20.1
x
|
-
|
-
|
-
|
3.13
x
|
EV / Revenue
|
77.8
x
|
53.2
x
|
93.5
x
|
20.1
x
|
-
|
-
|
-
|
3.13
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-0.54
x
|
-0.35
x
|
-0.27
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-187%
|
-284%
|
-365%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,517
|
2,495
|
5,771
|
7,434
|
9,399
|
9,400
|
-
|
-
|
Reference price
2 |
25.65
|
10.66
|
8.100
|
1.350
|
0.6800
|
1.310
|
1.310
|
1.310
|
Announcement Date
|
25/03/20
|
19/03/21
|
31/03/22
|
30/03/23
|
28/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.5
|
0.5
|
0.5
|
0.5
|
-
|
-
|
-
|
3.933
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-20.56
|
-18.49
|
-21.01
|
-24.92
|
-21.03
|
-22.69
|
-26.49
|
-36.75
|
Operating Margin
|
-4,113%
|
-3,697.2%
|
-4,201.4%
|
-4,984.4%
|
-
|
-
|
-
|
-934.32%
|
Earnings before Tax (EBT)
1 |
-18.67
|
-23.33
|
-22.15
|
-37.46
|
-20.8
|
-22.96
|
-26.89
|
-36.8
|
Net income
1 |
-16.85
|
-21.48
|
-20.77
|
-35.9
|
-19.52
|
-22.96
|
-26.89
|
-36.8
|
Net margin
|
-3,370.4%
|
-4,296.8%
|
-4,153.8%
|
-7,179.6%
|
-
|
-
|
-
|
-935.59%
|
EPS
2 |
-11.55
|
-10.05
|
-3.830
|
-5.030
|
-2.160
|
-2.267
|
-1.710
|
-1.730
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-
|
-23
|
-35
|
-45
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,144.07%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/03/20
|
19/03/21
|
31/03/22
|
30/03/23
|
28/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.125
|
0.125
|
0.125
|
0.125
|
0.125
|
0.125
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-5.062
|
-5.491
|
-5.842
|
-5.978
|
-6.174
|
-6.927
|
-5.684
|
-5.474
|
-3.904
|
-5.968
|
-5.359
|
-5.603
|
-5.6
|
-5.965
|
Operating Margin
|
-4,049.6%
|
-4,392.54%
|
-4,673.6%
|
-4,782.4%
|
-4,939.2%
|
-5,541.75%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-5.411
|
-5.605
|
-10.47
|
-6.043
|
-6.148
|
-14.8
|
-5.591
|
-5.559
|
-3.477
|
-6.168
|
-5.426
|
-5.77
|
-5.633
|
-6.098
|
Net income
1 |
-5.411
|
-4.221
|
-10.47
|
-6.043
|
-6.148
|
-13.23
|
-5.591
|
-5.559
|
-3.477
|
-4.888
|
-5.426
|
-5.77
|
-5.633
|
-6.098
|
Net margin
|
-4,328.8%
|
-3,376.85%
|
-8,379.2%
|
-4,834.4%
|
-4,918.4%
|
-10,585.95%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.9000
|
-3.620
|
-1.820
|
-0.8700
|
-0.8700
|
-1.610
|
-0.6800
|
-0.6100
|
-0.3700
|
-0.5200
|
-0.5667
|
-0.6033
|
-0.5867
|
-0.5100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/11/21
|
31/03/22
|
16/05/22
|
15/08/22
|
14/11/22
|
30/03/23
|
11/05/23
|
10/08/23
|
14/11/23
|
28/03/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-
|
-23
|
-35
|
-45
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
-
|
-
|
1
|
1
|
1
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
25.42%
|
Announcement Date
|
25/03/20
|
19/03/21
|
31/03/22
|
30/03/23
|
28/03/24
|
-
|
-
|
-
|
Last Close Price
1.31
USD Average target price
12
USD Spread / Average Target +816.03% Consensus |
1st Jan change
|
Capi.
|
---|
| +92.65% | 12.5M | | +9.15% | 105B | | -1.08% | 104B | | +5.79% | 22.94B | | -11.55% | 22.34B | | -7.01% | 19.25B | | -37.08% | 17.08B | | -9.91% | 16.96B | | +7.55% | 14.16B | | +40.04% | 12.63B |
Bio Therapeutic Drugs
|